Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex: A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2016.3545
Abstract: Importance Inhibitors of mammalian target of rapamycin complex 1, such as sirolimus, effectively target skin lesions in tuberous sclerosis complex (TSC). However, systemic treatment causes adverse effects, and topical sirolimus has shown promise in the… read more here.
Keywords: tuberous sclerosis; topical sirolimus; trial; treatment ... See more keywords
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2018.0464
Abstract: Importance Facial angiofibromas occur in approximately 75% of individuals with tuberous sclerosis complex (TSC), causing substantial morbidity and disfigurement. Current therapies are partially effective, uncomfortable, produce scarring, and need repeating to treat recurrence. Objective To… read more here.
Keywords: topical rapamycin; trial; vehicle; group ... See more keywords
Polymeric micelle formulations for the cutaneous delivery of sirolimus: a new approach for the treatment of facial angiofibromas in tuberous sclerosis complex.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2021.120736
Abstract: Facial angiofibromas are benign tumors characteristic of tuberous sclerosis complex. The disease involves the mTOR pathway and the cutaneous manifestation responds to topical treatment with sirolimus (SIR). However, there are no approved topical SIR products… read more here.
Keywords: tuberous sclerosis; sclerosis complex; delivery; facial angiofibromas ... See more keywords
Photodynamic Therapy in a Patient with Facial Angiofibromas due to Tuberous Sclerosis Complex.
Sign Up to like & getrecommendations! Published in 2019 at "Photodiagnosis and photodynamic therapy"
DOI: 10.1016/j.pdpdt.2019.08.009
Abstract: The facial angiofbromas due to tuberous sclerosis complex produced significant social and emotional distress for affected individuals, but there is no specific therapeutic strategy up to now. Herein, we report a case of facial angiofibromas… read more here.
Keywords: tuberous sclerosis; photodynamic therapy; sclerosis complex; facial angiofibromas ... See more keywords
Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Dermatology"
DOI: 10.1111/bjd.16397
Abstract: The use of topical rapamycin or rapalog, an mTOR inhibitor, has shown promising results in treating facial angiofibromas (FA) in children with Tuberous Sclerosis Complex (TSC). Nevertheless, several issues remain: the effectiveness, stability and tolerability… read more here.
Keywords: tuberous sclerosis; sclerosis complex; rapamycin rapalog; facial angiofibromas ... See more keywords
The efficacy and safety of topical rapamycin–calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double‐blind, randomized clinical trial
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.18949
Abstract: The efficacy of topical rapamycin is well documented for tuberous sclerosis complex (TSC)‐related facial angiofibromas (FAs). Calcitriol has been shown to lessen skin fibrosis and may be therapeutically beneficial to FAs. read more here.
Keywords: topical rapamycin; tuberous sclerosis; sclerosis complex; efficacy ... See more keywords
Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.18693
Abstract: Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome causing hamartomatous growths in multiple organs. Facial angiofibromas occur in up to 80% of patients and can be highly disfiguring. Treatment for these lesions is… read more here.
Keywords: topical rapamycin; facial angiofibromas; use topical; treatment ... See more keywords
Impact of facial angiofibromas in tuberous sclerosis complex and reported efficacy of available treatments
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.967971
Abstract: Tuberous Sclerosis Complex (TSC) is a genetic condition which leads to a loss of inhibition of cellular growth. Facial angiofibromas (FAs) are hamartomatous growths associated with TSC that appear as multiple small, erythematous papules on… read more here.
Keywords: facial angiofibromas; survey; tuberous sclerosis; sclerosis complex ... See more keywords
Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10040826
Abstract: Previous studies have suggested that the topical mechanistic target of rapamycin (mTOR) inhibitors may be effective in treating facial angiofibromas in patients with tuberous sclerosis complex (TSC). Various concentrations of topical sirolimus for TSC have… read more here.
Keywords: topical sirolimus; facial angiofibromas; angiofibromas; analysis ... See more keywords